drugset

drugset / Trial / NCT01823679

Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin

NCT01823679 ↗

Phase 2 Terminated 2 enrolled Stanford University National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

Phase 2 evaluation of capecitabine in patients with advanced or recurrent squamous cell carcinoma of the skin.

Timeline

Start: 2013-03
Primary completion: 2014-05
Completion: 2014-05

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	500 mg/m2	Oral

Indications